Across TCGA pan-cancer cohorts, BCL9L mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of BCL9L’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where BCL9L mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types BCL9L is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.
CCRCC, LUAD, and HNSC are the cancer types where BCL9L tumor–normal differential expression is most reproducible.
mass-spec protein tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BCL9L mass-spec protein (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.